{
    "clinical_study": {
        "@rank": "9864", 
        "arm_group": {
            "arm_group_label": "Multiple drug microinjection", 
            "arm_group_type": "Experimental", 
            "description": "Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin and/or prednisolone"
        }, 
        "brief_summary": {
            "textblock": "Many cancer patients are prescribed drugs to which their cancer is already resistant - and\n      thus suffer toxicity with no potential for benefit. Previous attempts to assess\n      chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human\n      patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph\n      nodes in situ respond to standard of care therapeutics precisely microinjected with the\n      CIVO(tm) microdosing system."
        }, 
        "brief_title": "Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or over\n\n          -  Newly diagnosed lymphoma that would typically be treated with agents in the R-CHOP\n             regimen OR recurrent/progressive lymphoma in patients who were previously treated\n             with at least one drug in the R-CHOP regimen or bendamustine.\n\n          -  At least one cancerous lymph node that is considered accessible for percutaneous\n             injection by the investigator and that is at least 2 cm in longest dimension.\n\n          -  ECOG performance status of 0-2 (or a Karnofsky performance status of >50%).\n\n          -  Labs required for enrollment: Absolute neutrophil count > 1000/mm3, platelet count >\n             50,000/mm3, hematocrit > 25%, and coagulation, liver and renal function tests within\n             normal limits.\n\n        Exclusion Criteria:\n\n          -  Lymphoma patients in which the delay of up to 3 days to surgery or other factors\n             associated with the study are not feasible.\n\n          -  Patients with central nervous system disease.\n\n          -  Any therapy that is potentially immunosuppressive or has anticancer activity in the 4\n             weeks prior to device microinjection.\n\n          -  Patients with active fungal, viral, or bacterial infections\n\n          -  Pregnant women.\n\n          -  Inability to give informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831505", 
            "org_study_id": "PRS-1", 
            "secondary_id": "R42CA144104-02"
        }, 
        "intervention": {
            "arm_group_label": "Multiple drug microinjection", 
            "intervention_name": "Multiple drug microinjection:  rituximab, vincristine, doxorubicin and/or prednisolone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Rituximab", 
                "Prednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Vincristine", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "personalized medicine", 
            "in vivo drug sensitivity", 
            "chemotherapy", 
            "lymphoma", 
            "microinjection"
        ], 
        "lastchanged_date": "April 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Seattle Cancer Care Alliance"
            }, 
            "investigator": {
                "last_name": "Oliver W Press, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System", 
        "overall_contact": {
            "email": "clinicaltrials@presagebio.com", 
            "last_name": "Clinical Trials Coordinator", 
            "phone": "(800) 530-5404"
        }, 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center", 
            "last_name": "Oliver W Press, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of the response to locally injected drugs", 
            "safety_issue": "No", 
            "time_frame": "1-3 days post injection after injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831505"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Evaluate the safety profile of multiple simultaneous microinjections using custom syringe", 
            "safety_issue": "Yes", 
            "time_frame": "up to 28 days"
        }, 
        "source": "Presage Biosciences", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Fred Hutchinson Cancer Research Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Presage Biosciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}